All In Biotech

Drug Trial Radar · NCT04432584

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 190 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

190

Planned (sponsor's estimate)

Start

Sep 30, 2020

Primary completion

Apr 18, 2027

Study completion Apr 18, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Jun 16, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • CrovalimabDrug

    Dosing depends on body weight. Participants will be dosed as follows: * 5 kg to \< 12 kg: 100 mg IV on Week 1 Day 1 (W1D1); 85 mg SC on Week 1 Day 2 (W1D2) and Q2W from Week 3 until end of study * 12 kg to \< 20 kg: 200 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 170 mg SC, Q2W from Week 5 until end of study * 20 kg to \< 30 kg: 300 mg IV on W1D1; 85 mg SC on W1D2, Weeks 2, 3 and 4; 340 mg SC, Q4W from Week 5 until end of study * 30 kg to \< 40 kg: 400 mg IV on W1D1; 170 mg SC on W1D2, Weeks 2, 3 and 4; 510 mg SC, Q4W from Week 5 until end of study * 40 kg to \< 100 kg: 1000 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 680 mg SC, Q4W from Week 5 until end of study * 100 kg: 1500 mg IV on W1D1; 340 mg SC W1D2, Weeks 2, 3 and 4; 1020 mg SC, Q4W from Week 5 until end of study.

  • EculizumabDrug

    Eculizumab will be administered at a dose of 900 mg Q2W, as per the dosing schedule described above.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Adverse Events (AEs) and by SeverityTime frame: Up to approximately 6 years
  2. Percentage of Participants With Injection-site Reactions, Infusion-related Reactions, Hypersensitivity and Infections (including Meningococcal Meningitis)Time frame: Up to approximately 6 years
  3. Percentage of Participants With Adverse Events (AEs) Leading to Study Drug DiscontinuationTime frame: Up to approximately 6 years
  4. Percentage of Participants With Clinical Manifestations of Drug-target-drug Complex (DTDC) Formation Amongst Those Participants Who Switched to Crovalimab Treatment From Eculizumab Treatment or Ravulizumab TreatmentTime frame: Up to approximately 6 years

Locations

80 sites in 24 countries. Site status is shown where the registry gives one.

  • Carolinas Healthcare System

    Charlotte, North Carolina

  • Nationwide Children's Hospital

    Columbus, Ohio

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • AZ Delta Campus Westlaan

    Roeselare, Belgium

  • Beneficencia Portuguesa de Sao Paulo

    São Paulo, Brazil

  • Chronos Pesquisa Clinica

    Taguatinga, Federal District, Brazil

  • Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clínicas de Porto Alegre X

    Porto Alegre, Rio Grande do Sul, Brazil

  • Instituto Joinvilense de Hematologia E Oncologia

    Joinville, Santa Catarina, Brazil

  • Hospital das Clínicas FMRP-USP

    Ribeirão Preto, São Paulo, Brazil

  • *X*CEPHO - Centro de Estudos e Pesquisas em Hematologia e Oncologia

    Santo André, São Paulo, Brazil

  • Hospital Sírio-Libanês

    São Paulo, São Paulo, Brazil

  • Hospital Paulistano

    São Paulo, São Paulo, Brazil

  • Ustav hematologie a krevni transfuze

    Prague, Czechia

  • North Estonia Medical Centre Foundation

    Tallinn, Estonia

  • Hopital Claude Huriez - CHU Lille

    Lille, France

  • Institut Paoli Calmette

    Marseille, France

  • Universitaetsklinikum Aachen AOeR

    Aachen, Germany

  • ELBLANDKLINIKUM Riesa

    Riesa, Germany

  • General Hospital of Athens LAIKO

    Athens, Greece

  • Attikon University General Hospital

    Athens, Greece

  • Prince of Wales Hospital

    Hong Kong, Hong Kong

  • Semmelweis Egyetem

    Budapest, Hungary

  • St James's Hospital

    Dublin, Ireland

  • Azienda Unita Sanitaria Locale- Ravenna

    Ravenna, Emilia-Romagna, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy

  • Fondazione IRCCS CA? Granda Ospedale Maggiore Policlinico

    Milan, Lombardy, Italy

  • Azienda Ospedaliera Città della Salute e della Scienza di Torino

    Turin, Piedmont, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Tuscany, Italy

  • Fujita Health University Hospital

    Aichi, Japan

  • Kobe University Hospital

    Hyōgo, Japan

  • Tokushukai Takasago Seibu Hospital

    Hyōgo, Japan

  • Ishikawa Prefectural Central Hospital

    Ishikawa, Japan

  • Tokai University Hospital

    Kanagawa, Japan

  • Mie University Hospital

    Mie, Japan

  • Japanese Red Cross Society Suwa Hospital

    Nagano, Japan

  • Nagasaki University Hospital

    Nagasaki, Japan

  • Sasebo City General Hospital

    Nagasaki, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan

  • The University of Osaka Hospital

    Osaka, Japan

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.